BS_1RXZ3BP7
low-grade glioma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- low-grade glioma
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- low-grade glioma
- overall_survival_months
- 96.81340341655715
- age_years
- 6.09
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
5 twins match this tumor's tissue · 5 come from a different tissue of origin ← cross-tissue dominant
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_ZV9Z3SY6 | pilocytic astrocytoma | — | 0.954 |
| 2 | MDT-AP-2869 | Med | Medulloblastoma | 0.950 |
| 3 | SRR1797296 | — | cohortMD2 | 0.944 |
| 4 | TCGA-22-1000-01A-01R-A32Z-07 | — | cohortSQ1 | 0.937 |
| 5 | MDT-AP-0384 | Med | Medulloblastoma | 0.937 |
| 6 | SRR5088824 | — | — | 0.936 |
| 7 | ERR2598314 | fetal | fetal | 0.936 |
| 8 | SRR5088860 | — | — | 0.930 |
| 9 | MDT-AP-3277 | Med | Medulloblastoma | 0.930 |
| 10 | TCGA-A2-A0EN-01A-13R-A084-07 | — | A | 0.930 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| IL6_JAK_STAT3_SIGNALING | 0.575 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.561 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.548 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.545 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.514 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.501 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.497 | Idelalisib | — uncovered |
| COMPLEMENT | 0.465 | Inavolisib | — uncovered |
| COAGULATION | 0.463 | Binimetinib | — uncovered |
| KRAS_SIGNALING_UP | 0.433 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.395 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.379 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.376 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.373 | Inavolisib | — uncovered |
| MYOGENESIS | 0.367 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.269 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.263 | Temsirolimus | — uncovered |
| HYPOXIA | 0.257 | Idelalisib | — uncovered |
| NOTCH_SIGNALING | 0.256 | Inavolisib | — uncovered |
| XENOBIOTIC_METABOLISM | 0.244 | Inavolisib | — uncovered |